Clinical Trial

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Multicenter Parallel 2 Cohort Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated, and T474 Gatekeeper Mutant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-14.
Status change: Not Yet Recruiting → Recruiting 2025-08-11
Trial Details
NCT Number NCT06978088
Lead Sponsor Zulfa Omer
Collaborators: Newave Pharmaceutical Inc
Conditions Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma, CLL/SLL, Chronic Lymphocytic Leukemia
Enrollment 34 participants
Start Date 2025-06-01
Primary Completion 2029-06-01 (estimated)
Study Completion 2034-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-14